Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

After Last Week’s FDA Decision, Everyone’s Talking About What’s Next

Aug 16 • 5 min read

After last week’s rejection of MDMA, everyone has been conjecturing about the future of psychedelics as medicine. Questions surrounding all the delays and need for more capital have taken hold of mainstream media. Throughout all of this, one of the most interesting conversations we’ve heard recently is Vivek Ramaswamy’s interview with Balaji Srinivasan. While Psychedelic…

UC Davis Scientists Introduce Tool to Reveal Psychedelics’ Effects on Neurons

Aug 14 • 3 min read

In recent years, the potential of psychedelic drugs in treating mental health disorders like substance use disorder, PTSD, and depression has garnered increasing attention. Numerous studies have highlighted the therapeutic effects of psychedelic compounds such as psilocybin, DMT, and LSD, particularly their ability to promote the growth and strengthening of neurons in the prefrontal cortex….

Want To Work in Psychedelics? The Industry Needs More Trial Screeners.

Aug 14 • 15 min read

Psychedelic clinical studies have become a cornerstone in the evolving landscape of mental health treatment. With conditions like depression, PTSD, and anxiety reaching alarming prevalence, the medical community is increasingly turning to innovative approaches, including the controlled use of psychedelics. Substances like psilocybin, MDMA, and LSD, once associated with the counterculture movement of the 1960s,…

Denial of Lykos’ MDMA-Assisted PTSD Therapy Followed by Retraction of Related Studies

Aug 12 • 3 min read

A day after the regulatory rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD, the scientific community faced another setback as a prominent medical journal retracted three significant studies on the same subject. On Saturday, the journal Psychopharmacology formally pulled three papers that investigated the use of MDMA, a psychoactive drug, for treating post-traumatic stress disorder…

FDA Denies Lykos and Requests Another Trial

Aug 9 • 3 min read

The FDA issued a complete response letter regarding Lykos’ drug application for its midomafetamine capsules, an MDMA-based treatment designed for adults with PTSD. The agency, in a statement released on Friday afternoon, requested an additional Phase 3 trial to better assess the drug’s safety and efficacy. Amy Emerson, CEO of Lykos, expressed her deep disappointment…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354